Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position

Posted on November 15, 2024 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast Track and Orphan Drug Designations from the FDA. The company also licensed TPI 287, a late-stage candidate for brain malignancies, with plans for FDA engagement on future studies. CNS ended the quarter with $7.0 million in cash and additional funding, ensuring operations through Q2 2025.

To view the full press release, visit https://ibn.fm/x8oGM

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Partners with National Auto Fleet Group to Deliver Bollinger B4 EV Trucks to Government Fleets

Posted on November 15, 2024 by MissionIR

Mullen Automotive (NASDAQ: MULN) announced a partnership with National Auto Fleet Group (“NAFG”) to sell its all-electric Class 4 Bollinger B4 commercial trucks to government agencies via NAFG’s Sourcewell-awarded contract. The Bollinger B4, designed with fleet and upfitter input, offers a 185-mile range, a payload of 7,394 pounds, and a robust chassis protecting its 158-kilowatt-hour battery pack. This collaboration provides Bollinger Motors with a streamlined pathway to secure government contracts, aligning with electrification goals of municipalities and agencies. Recent milestones for Bollinger include regulatory certifications, production launch, and multiple fleet agreements, bolstered by partnerships with key dealers, service centers, and battery suppliers.

To view the full press release, visit https://ibn.fm/zZmMk

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Mullen Automotive Inc. MULN | Leave a comment

MissionIRNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Reports Q3 Financials, Highlights Growth from Progressive Care and Outfitter Satellite Acquisitions

Posted on November 14, 2024 by MissionIR

NextPlat (NASDAQ: NXPL, NXPLW)  reported Q3 2024 results reflecting the impact of its recent acquisitions, including Progressive Care and Outfitter Satellite, which contributed to consolidated revenues of $15.4 million. While healthcare revenue declined due to lower prescription reimbursement rates, e-Commerce revenue saw a 31% increase, largely from the Outfitter acquisition. The company recorded a net loss of $4.2 million due to increased expenses, including a non-cash impairment of Progressive Care’s intangible assets. Recent developments include expanding healthcare contracts and satellite communication device sales, along with a strengthened e-commerce presence in China and the UK. NextPlat projects ongoing growth from integration efficiencies and increased global demand in its healthcare and e-commerce sectors.

To view the full press release, visit: https://ibn.fm/R7UVm

About NextPlat Corp

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in NextPlat Corp. NXPL | Leave a comment

MissionIRNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) – A Gem in the Mining Sector

Posted on November 13, 2024 by MissionIR

McEwen Mining (NYSE: MUX) (TSX: MUX) is positioned to benefit from increased investor interest in precious metals as well as growing demand for critical minerals. “McEwen Mining is a gold and silver producer with operations across the Americas, including Nevada, Canada, Mexico, and Argentina. In addition to its core business of precious metals, the company has significant exposure to copper through its 48% ownership of McEwen Copper, a subsidiary responsible for the advanced-stage Los Azules project in Argentina. Led by Rob McEwen, a seasoned mining veteran with a personal investment of $225 million, McEwen Mining is establishing itself as a significant player in the critical minerals space.”

“The company’s vision is simple: maximize asset productivity, improve profitability, and ultimately increase share value while offering returns to investors. With a seasoned leader at the helm, a diverse portfolio, and a keen focus on sustainability, McEwen Mining stands poised to unleash significant value, offering investors a golden opportunity to tap into an underappreciated gem.”

To view the full article, visit https://ibn.fm/vmTDT

About McEwen Mining Inc.
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it owns approximately 47.7% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing its share price and providing a yield. Rob McEwen, MUX’s chairman and chief owner, has personally provided the company with $220 million and takes an annual salary of $1.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in McEwen Mining Inc. MUX | Leave a comment

Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease

Posted on November 13, 2024 by MissionIR
  • Annovis provided business and financial updates for Q3 2024, spotlighting progress toward pivotal buntanetap trials in Alzheimer’s disease.
  • The FDA has cleared Annovis to proceed with a Phase 3 program, which will include a 6-month study to confirm buntanetap’s symptomatic benefits (beginning Q1 2025) and an 18-month study to explore potential disease-modifying effects.
  • Matthew Peterson, Ph.D., was appointed as Senior Clinical Scientist and will oversee quality and rigor in upcoming clinical trials.
  • Annovis filed three new patents for innovative combination therapies, involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), and a combination of all three.
  • As of Nov. 8, 2024, the company reported a cash position of $13.6 million, providing sufficient runway to support all Phase 3 preparatory activities and to initiate the pivotal Phase 3 Alzheimer’s study in Q1 2025.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), concluded the third quarter with significant milestones achieved and a clear path forward for its lead candidate, buntanetap.

Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying, positioning buntanetap as a potential breakthrough in treating neurodegenerative diseases.

The drug candidate has been shown effective in improving the health of nerve cells and therefore cognition in AD and cognition and motor function in PD patients. Annovis recently completed a Phase 2/3 AD study, with encouraging results that were presented to the U.S. Food and Drug Administration (“FDA”) on Oct. 10, 2024. During that meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies: a 6-month study aimed at confirming buntanetap’s symptomatic effects, set to begin in Q1 2025, and an 18-month study designed to demonstrate potential disease-modifying effects. The FDA also recognized buntanetap’s safety, raising no concerns regarding liver enzyme levels, drug interactions, dose selection, pharmacokinetics, population pharmacokinetics and confirmed that development could proceed using the new crystal form of buntanetap.

To ensure the successful completion of upcoming clinical trials, the company appointed Matthew Peterson, Ph.D., as Senior Clinical Scientist, who will be responsible for quality and rigor in the next studies.

“The third quarter was a milestone period that has clearly defined our path forward for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “With FDA approval to launch confirmatory Phase 3 studies in early AD, our team is focused on initiating a 6-month pivotal trial early next year. We also bolstered our IP portfolio with new patents for combination therapies involving buntanetap, reinforcing our commitment to finding innovative solutions for these debilitating conditions.”

The three new patents, filed on Sept. 30, 2024, cover combination therapies involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, creating a multifaceted approach to treating neurodegenerative diseases.

During the third quarter, Annovis presented two posters at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid, showcasing buntanetap’s efficacy in Phase 2/3 AD study and the biomarker data.

In terms of Q3 financial results, the company announced that it has an adequate runway for all Phase 3 preparatory studies and for entering the pivotal Phase 3 AD study in Q1 2025, having cash and cash equivalents of $13.6 million as of Nov. 8, 2024.

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Annovis Bio Inc. ANVS | Leave a comment

Kairos Pharma Ltd. (NYSE American: KAPA) Is ‘One to Watch’

Posted on November 12, 2024 by MissionIR
  • Kairos Pharma’s partnership with Cedars-Sinai Medical Center enhances clinical trial efficiency and accelerates the development of new therapeutic solutions.
  • The company holds a robust intellectual property portfolio with patents extending through 2040, providing a strong competitive advantage in the oncology market.
  • ENV105, Kairos’s lead drug candidate, shows promise in reversing drug resistance in prostate and lung cancers, addressing key markets with high demand for novel treatments.
  • Positioned in high-growth oncology segments, Kairos Pharma meets substantial market needs, driven by the increasing global incidence of drug-resistant cancers.
  • The company’s focus on biomarker development improves patient targeting, enhancing therapy success rates and underscoring its commitment to precision medicine.

Kairos Pharma (NYSE American: KAPA) is a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics that target drug resistance and immune suppression, two significant barriers in effective cancer treatment. By addressing these mechanisms, Kairos aims to restore the efficacy of standard cancer treatments while enhancing the body’s natural immune responses against tumors.

The company’s mission is to develop a diverse portfolio of drug candidates to provide novel options for patients with limited treatment pathways. Kairos is advancing its therapeutic pipeline with a focus on partnerships, precision medicine and clinical trial efficiency, moving closer to delivering new solutions for durable cancer remissions and improved patient quality of life.

Headquartered in Los Angeles, California, Kairos Pharma combines research excellence with patient-centered care. Led by an accomplished team of scientists and executives, the company is committed to transforming the cancer treatment landscape through next-generation therapeutic solutions that meet the highest standards of efficacy and safety.

Development Pipeline

Kairos Pharma’s development pipeline features multiple candidates across clinical and preclinical stages, each targeting unique mechanisms of resistance to cancer treatment:

  • ENV105: Currently in a Phase 2 trial for castrate-resistant prostate cancer, ENV105 is administered in combination with Apalutamide to overcome anti-androgen resistance. The company recently dosed the first patient in this trial, marking an important milestone in advancing prostate cancer treatment. ENV105 is also in a Phase 1 trial for EGFR-driven non-small cell lung cancer, where it is combined with Osimertinib to address resistance in this hard-to-treat cancer type. Kairos’s partnership with PreCheck Health Services supports the confirmation of biomarkers to identify patients most likely to benefit from ENV105, enhancing precision in patient selection.
  • KROS201: This candidate has received IND clearance for glioblastoma and focuses on activating T cells outside the body to target and destroy tumor cells, specifically addressing aggressive and treatment-resistant cancers.
  • KROS101: Designed to increase the number and efficacy of T cells, KROS101 shows promise in enhancing the immune system’s response to cancer, complementing existing immunotherapies.
  • KROS102: Targeted at autoimmune diseases, KROS102 works by decreasing T cell activity, potentially offering a new approach to managing autoimmune conditions.
  • KROS301 and KROS401: These candidates focus on inhibiting cancer cell growth and mitigating immune suppression in advanced cancers, including triple-negative breast cancer.

Intellectual Property Portfolio

Kairos Pharma’s intellectual property portfolio secures exclusive rights to its advanced drug technologies and forms the backbone of its innovative approach in oncology. Key patents cover ENV105, protecting its mechanism of targeting CD105 to reverse resistance in prostate and lung cancers. This IP extends internationally and is valid until 2040, ensuring a secure competitive position in the cancer therapeutics market.

Additionally, Kairos’s portfolio includes patents for the KROS series (KROS101, KROS201, KROS301, and KROS401), covering applications in both cancer and autoimmune diseases. Many of these patents were developed through research at Cedars-Sinai Medical Center, from which Kairos holds exclusive, worldwide licensing rights. This robust IP framework positions the company to leverage its unique technologies across multiple therapeutic areas, with a clear focus on addressing unmet medical needs in cancer and immune-related conditions.

Market Opportunity

Kairos Pharma is positioned to address high-growth oncology markets that demand innovative solutions to overcome drug resistance. The prostate cancer market, estimated at $11.3 billion, and the EGFR-driven lung cancer market, valued at $14 billion, represent key segments where Kairos’s drug candidates, particularly ENV105, have significant potential. Rising cancer incidence globally further underscores the demand for effective treatments that can restore sensitivity to existing therapies.

The broader immunotherapy market, which is projected to reach up to $148 billion by 2030, represents another major growth area for Kairos Pharma. The company’s targeted approach aligns with the precision medicine trend in oncology, enabling the development of therapies tailored to patient needs. By addressing underserved areas in cancer treatment, Kairos is poised to meet substantial unmet needs in the oncology and immunotherapy markets.

Leadership Team

Dr. John S. Yu serves as CEO and Chairman of Kairos Pharma. An accomplished neurosurgeon and immunotherapy expert, Dr. Yu has developed numerous investigational drugs and led multiple clinical trials. He holds degrees from Stanford, Harvard Medical School and MIT, and his career is centered on groundbreaking research in cancer therapeutics.

Dr. Neil Bhowmick, Chief Scientific Officer, brings over 20 years of extensive biochemistry expertise, including filing and prosecuting patents for therapeutics and devices, authoring 110 peer-reviewed publications, and leading foundational and pre-clinical cancer research. He has successfully obtained regulatory approvals and conducted clinical trials. With more than 15 years of continuous NCI/NIH funding, Dr. Bhowmick’s work has been cited over 15,000 times. He holds six patents, including innovations in biomarker detection platforms and stromal-targeted therapeutics such as ENV 105 and ENV 205.

Dr. Ramchandran Murali, VP of Research and Development, is an immunologist and molecular engineer recognized for his work in developing pharmacological agents to counter immune suppression in cancer. His extensive research background is instrumental in advancing Kairos’s innovative drug pipeline.

Doug Samuelson, Chief Financial Officer, brings over 25 years of experience in finance, having served as CFO for various biopharma companies. His expertise in financial management and regulatory compliance provides strong support to Kairos Pharma’s strategic initiatives as a clinical-stage company.

For more information, visit the company’s website at KairosPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA          

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Kairos Pharma Ltd. KAPA | Leave a comment

SOBRsafe Inc. (NASDAQ: SOBR) Raises $8.2M in Private Placement Offering Amid Ongoing Expansion Efforts, Marketing Campaign to Drive Growth

Posted on November 12, 2024 by MissionIR
  • Alcohol screening and monitoring solutions provider SOBRsafe recently closed on a private placement, which raised $8.2 million in gross proceeds
  • The company plans to use the net proceeds from the private placement for working capital and general corporate purposes, including possibly boosting its expansion efforts
  • With an ongoing national marketing campaign, SOBRsafe is presenting its revolutionary alcohol screening and monitoring technologies to 45,000 behavioral health providers in the U.S.
  • In addition, the company initiated sales activities in Australia and New Zealand through a partnership with a channel partner, and is partnering with companies in India and Italy for proof-of-concept installations of SOBRcheck(TM) or SOBRsure(TM)

SOBRsafe (NASDAQ: SOBR), a provider of next-generation transdermal alcohol screening and monitoring solutions, recently raised $8.2 million in gross proceeds from a private placement with certain institutional investors. The company expects to use the net proceeds from the offering for working capital and general corporate purposes (https://ibn.fm/xM074).

The closing of this offering, announced on October 9, came amid the company’s ongoing expansion efforts, with some of the proceeds expected to boost these initiatives. In August, SOBRsafe launched a national campaign that seeks to introduce the company’s technology offerings – the SOBRcheck(TM) stationary alcohol screening device, the SOBRsure(TM) discreet alcohol monitoring wristband, and the SOBRsafe(TM) software platform powering reporting – to behavioral health providers and, as a result, drive sales growth into 2025.

The company aims to present its technology to over 45,000 decision-makers in the behavioral health space, having partnered with recognized leaders in public relations and digital and social media marketing. “We are working with national communications leaders to build the SOBRsafe brand, grow demand, and gain market share. This effort will move us closer to improving patient outcomes and saving lives,” said SOBRsafe CEO and Chairman Dave Gandini of the national campaign (https://ibn.fm/8DTo2).

The campaign aligns with the company’s focus on the behavioral health vertical. In addition, it is intended to increase the number of customer accounts that SOBRsafe has added in 2024, which stood at 35 as of September 12. The company accomplished this feat with “a limited investment in marketing and brand building,” according to Gandini’s message in a recent video update (https://ibn.fm/V0uKi). The ongoing national campaign, therefore, may result in considerably more customer accounts during the remainder of 2024 and into 2025.

SOBRsafe is also strategically implementing its international expansion. Strategic in its approach, the company collaborates with interested local or regional service providers and companies, initially via paid proofs of concept and, if successful, fully fledged partnerships. The company has used – or is using – this approach in India, Italy, Australia, and New Zealand.

In India, a critical infrastructure developer that owns and operates various infrastructure assets across India and Southeast Asia is installing SOBRsafe’s SOBRcheck(TM) device at points of entry to screen employees. This paid proof-of-concept installation is intended to promote alcohol safety, helping SOBRsafe “establish a new standard for alcohol screening in India” and provide “value to employers while saving lives,” according to Gandini (https://ibn.fm/40AHH).

An employer in Italy has also selected the company’s SOBRsure(TM) wristband for remote continuous monitoring of fleet drivers. This proof-of-concept application of the device will help verify both the location and sobriety of drivers, benefiting the company, which operates a fleet of more than 10,000 vehicles. Gandini believes SOBRsure “can help European employers demonstrate compliance” with laws prohibiting commercial drivers from imbibing any amount of alcohol and do so in real-time and in a “passive, non-invasive manner.”

The proof-of-concept approach has proven successful in Australia and New Zealand, where, after a 90-day trial run, SOBRsafe initiated sales activities via a regional channel partner, Drug Testing Business Success. The channel partner plans to target the behavioral and justice spaces, availing the company’s products through a dedicated e-commerce website and a coalition of suppliers. “We’re excited about this new revenue stream in Australia and New Zealand, and we believe that this could accelerate broader global expansion,” conveyed Gandini (https://ibn.fm/IVmHi).

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in SOBRsafe Inc. SOBR | Leave a comment

MissionIRNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop

Posted on November 12, 2024 by MissionIR

Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. Maccecchini’s presentation, titled “One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer’s and Parkinson’s Patients. A Potential Path for Lewy Body Dementia?” will explore the potential of Annovis’s lead drug candidate, Buntanetap, to address neurodegenerative diseases by enhancing cognitive and motor functions, with implications for Lewy body dementia treatment.

To view the full press release, visit https://ibn.fm/pOQ1C

About Annovis Bio Inc.

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Annovis Bio Inc. ANVS | Leave a comment

AI Solutions Startup Secures $15m in Fundraising Round

Posted on November 12, 2024 by MissionIR

Cogna, an artificial intelligence software firm, just brought in $15 million in new backing. The company has the largest gas distribution network in Britain among its clients. This latest funding includes investment from key venture capital firms Chalfen Ventures and Notion Capital.

Cogna intends to use the funding to boost productivity and resolve inefficiencies within the operations of their target clientele. According to the company, they intend to use “precision solutions” in the diagnosis and fixing of those challenges faced by their customers. Their clients are currently within the manufacturing, utilities and energy sectors.

With this new funding, Cogna plans to spread its reach to customers within other industries. They also plan to broaden the scope of their automated artificial intelligence-supported factory making software solutions.

Currently, Cogna is making inroads into the enterprise resource planning niche as well as the market for IT consultancy services. These industries are currently worth $51 billion and $362.5 billion in revenue, respectively. Cogna CEO and co-founder Ben Peters said that traditional manufacturing industries had been sidelined by the digital revolution as a result of the complex and peculiar challenges that they faced. He added that Cogna was determined to design solutions tailored to the unique needs of manufacturing industries so that they, too, can register the productivity enhancement that AI solutions can deliver.

Peters expressed confidence that the new funding injected into Cogna would enable the company to address the different bottlenecks which have been holding back entities in different industries, and the AI solutions would allow employees to unlock their potential once mundane repetitive tasks were taken over by automated AI solutions.

Howard Forster, COO of Cadent Gas, said that with network piping to the tune of 82,000 miles and over 11 million customers, they needed a software provider that could match their physical infrastructure scale. Cogna was suited to their requirements and they were happy to work with the company to develop solutions for various needs, such as optimizing their procurement system and creating a system to manage gas escape.

As more companies like Cogna bring AI solutions to different industries and sectors, the rate at which AI penetrates different walks of life is bound to accelerate. As that happens, the infrastructure demand (data centers and system components) will grow. Metals like copper, silver and gold are crucial to this expansion and mining entities like McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) are well positioned to reap from the ongoing AI boom.

For more information, visit the company’s website at www.McEwenMining.com

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in McEwen Mining Inc. MUX | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Deemed ‘Awardable’ Vendor on US Department of Defense’s Tradewinds Solutions Marketplace

Posted on November 11, 2024 by MissionIR
  • The U.S. Department of Defense’s Chief Digital and Artificial Intelligence Office’s (“CDAO”) Tradewinds Solutions Marketplace is a comprehensive suite of tools and services for accelerating the procurement of emerging technologies by the Department of Defense (“DoD”).
  • D-Wave’s presence on the marketplace will enable DoD customers to more easily adopt the company’s annealing quantum computing technologies and solutions.

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, has been deemed “Awardable” through the Department of Defense (“DoD”) Chief Digital and Artificial Intelligence Office’s (“CDAO”) Tradewinds Solutions Marketplace, a premier suite of tools and services for accelerating the procurement and adoption of emerging technologies (https://ibn.fm/POyFC).

The marketplace will now include D-Wave’s annealing quantum computing technology alongside other offerings like artificial intelligence (“AI”)/machine learning (“ML”), data, and analytics capabilities. Designating D-Wave an “Awardable” vendor will enable DoD customers to more easily adopt the company’s powerful annealing quantum computing technologies and solutions to assist with achieving mission objectives (https://ibn.fm/SfKaB).

To achieve this designation, D-Wave submitted a video presenting actual use cases in which companies developed quantum optimization applications, including supply chain optimization, transportation logistics and other potential optimization problems that the DoD may be facing. Government customers interested in viewing the video solution (https://ibn.fm/sPnr6) can create a Tradewinds Solutions Marketplace account at tradewindAI.com.

“D-Wave is unique in that we are the only company that has a real-time cloud accessible quantum computer and quantum optimization applications in production today,” said Lorenzo Martinelli, chief revenue officer at D-Wave. “These critical technological achievements in quantum computing can move the Department of Defense beyond research to using technology that could help provide solutions today to challenges facing DoD and its service branches.”

D-Wave CEO Dr. Alan Baratz said it was an honor for the company to be included in the Tradewinds Solution Marketplace for its innovative technology and the potential ability to assist DoD with overcoming complex challenges. “The ‘Awardable’ status on the marketplace signifies that our technology meets the high standards required to sell to the U.S. government,” Dr. Baratz added. “D-Wave has a long history of developing quantum applications to address national security problems, and we look forward to working with U.S. defense operations to help them achieve mission objectives.”

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment